血脂水平对多发性骨髓瘤患者临床特点及预后的价值研究
Study on the Value of Blood Lipid Level in the Clinical Characteristics and Prognosis of Patients with Multiple Myeloma
DOI: 10.12677/acm.2024.143881, PDF,   
作者: 张 弘, 闫 慧, 王 伟*:青岛大学附属医院血液内科,山东 青岛
关键词: 多发性骨髓瘤血脂水平临床特点预后Multiple Myeloma Blood Lipid Level Clinical Characteristics Prognosis
摘要: 目的:探讨多发性骨髓瘤(Multiple Myeloma, MM)的脂质代谢特点以及血脂水平在MM患者临床特点及预后中的价值。方法:收集2017年7月至2023年2月青岛大学附属医院收治的初诊MM患者,分别分析MM患者血脂水平与临床分期、免疫球蛋白分型、治疗效果以及总生存期之间的相关性。结果:在TC、LDL、HDL、Apo-A1、Apo-B水平上,ISS分期I期患者高于II期和III期患者,差异有统计学意义(P < 0.05);轻链型患者的TC、LDL、Apo-A1、Apo-B水平高于IgG型和IgA型患者,差异有统计学意义(P < 0.05),IgG型患者的TC、LDL、Apo-B水平高于IgA型患者,差异有统计学意义(P < 0.05);经过四周期治疗后,缓解组患者的血脂相关指标水平均较治疗前升高,差异有统计学意义(P < 0.05);TC、LDL、Apo-A1、Apo-B低水平组患者总生存期更短,预后更差(P < 0.05)。结论:血脂水平在MM患者临床特点及预后中具有重要意义。
Abstract: Objective: To investigate the characteristics of lipid metabolism in multiple myeloma and the value of blood lipid levels in the clinical characteristics and prognosis of patients with multiple myeloma. Methods: We collected the patients with newly diagnosed multiple myeloma admitted to the Affiliated Hospital of Qingdao University from July 2017 to February 2023. The correlation between blood lipid levels and clinical stage, immunoglobulin typing, treatment effect and overall survival of patients with multiple myeloma was analyzed. Results: The levels of TC, LDL, HDL, Apo-A1 and Apo-B in patients with ISS stage I were higher than those in patients with ISS stage II and III, and the difference was statistically significant (P < 0.05). The levels of TC, LDL, Apo-A1 and Apo-B in patients with light chain type were higher than those in patients with IgG type and IgA type, and the difference was statistically significant (P < 0.05). The levels of TC, LDL and Apo-B in patients with IgG type were higher than those in patients with IgA type, and the difference was statistically significant (P < 0.05). After four cycles of treatment, the levels of blood lipid related indicators in the remission group were higher than those before treatment, and the difference was statistically significant (P < 0.05). The patients with low levels of TC, LDL, Apo-A1, and Apo-B had shorter overall survival and worse prognosis (P < 0.05). Conclusion: Blood lipid levels are of great significance in the clinical characteristics and prognosis of patients with multiple myeloma.
文章引用:张弘, 闫慧, 王伟. 血脂水平对多发性骨髓瘤患者临床特点及预后的价值研究[J]. 临床医学进展, 2024, 14(3): 1571-1581. https://doi.org/10.12677/acm.2024.143881

参考文献

[1] Kazandjian, D. (2016) Multiple Myeloma Epidemiology and Survival: A Unique Malignancy. Seminars in Oncology, 43, 676-681. [Google Scholar] [CrossRef] [PubMed]
[2] Kumar, S.K., Rajkumar, V., Kyle, R.A., et al. (2017) Multiple Myeloma. Nature Reviews Disease Primers, 3, Article No. 17046. [Google Scholar] [CrossRef] [PubMed]
[3] Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef
[4] Lazaris, V., Hatziri, A., Symeonidis, A., et al. (2021) The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges. Frontiers in Oncology, 11, Article 638288. [Google Scholar] [CrossRef] [PubMed]
[5] Choi, T., Choi, I.Y., Han, K., et al. (2021) Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects. Cancers, 13, Article 540. [Google Scholar] [CrossRef] [PubMed]
[6] Lim, J.S.L., Chong, P.S.Y. and Chng, W.J. (2022) Metabolic Vulnerabilities in Multiple Myeloma. Cancers, 14, Article 1905. [Google Scholar] [CrossRef] [PubMed]
[7] Rajkumar, S.V. (2016) Myeloma Today: Disease Definitions and Treatment Advances. American Journal of Hematology, 91, 90-100. [Google Scholar] [CrossRef] [PubMed]
[8] Dmoszyńska, A., Podhorecka, M., Roliński, J., et al. (2004) Influence of Lovastatin on BCL-2 and BAX Expression by Plasma Cells and T Lymphocytes in Short-Term Cultures of Multiple Myeloma Bone Marrow Mononuclear Cells. Polish Journal of Pharmacology, 56, 485-489.
[9] Van der Spek, E., Bloem, A.C., Van de Donk, N.W., et al. (2006) Dose-Finding Study of High-Dose Simvastatin Combined with Standard Chemotherapy in Patients with Relapsed or Refractory Myeloma or Lymphoma. Haematologica, 91, 542-545.
[10] Dai, Y., Khanna, P., Chen, S., et al. (2007) Statins Synergistically Potentiate 7-Hydroxystaurosporine (UCN-01) Lethality in Human Leukemia and Myeloma Cells by Disrupting Ras Farnesylation and Activation. Blood, 109, 4415-4423. [Google Scholar] [CrossRef] [PubMed]
[11] Jánosi, J., Sebestyén, A., Bocsi, J., et al. (2004) Mevastatin-Induced Apoptosis and Growth Suppression in U266 Myeloma Cells. Anticancer Research, 24, 1817-1822.
[12] Otsuki, T., Sakaguchi, H., Hatayama, T., et al. (2004) Effects of an HMG-CoA Reductase Inhibitor, Simvastatin, on Human Myeloma Cells. Oncology Reports, 11, 1053-1058. [Google Scholar] [CrossRef
[13] Schmidmaier, R., Baumann, P., Simsek, M., et al. (2004) The HMG-CoA Reductase Inhibitor Simvastatin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma by Geranylgeranylation of Rho Protein and Activation of Rho Kinase. Blood, 104, 1825-1832. [Google Scholar] [CrossRef] [PubMed]
[14] 王丽, 赵艳莉, 金瑄, 等. 多发性骨髓瘤患者的血清β2-MG、TNF-α、IL-6水平及其临床意义[J]. 海南医学, 2020, 31(12): 1527-1529.
[15] 叶筱颖, 王子峰, 张娟, 等. 多发性骨髓瘤患者肺部感染病原菌分布特征及血清β2-MG、CRP对肺部感染的诊断价值[J]. 中国病原生物学杂志, 2021, 16(9): 1069-1072.
[16] 费晓莉, 章帆, 张开基, 等. IL-32, Cys-C和β2-MG在多发性骨髓瘤患者外周血中的表达[J]. 西南大学学报(自然科学版), 2021, 43(3): 30-35.
[17] 张勇军. β2-微球蛋白在肿瘤诊断和监测中的应用价值[J]. 检验医学与临床, 2013, 10(6): 699 701.
[18] 左立辉, 李四强, 秦伟, 等. 血清SCD54、Presepsin水平对多发性骨髓瘤的诊断价值及与患者预后的关系[J]. 国际检验医学杂志, 2022, 43(9): 1124-1128.
[19] 蔡宜诺, 刘景华, 王吉刚, 等. 新诊断多发性骨髓瘤肾功能亚型组间细胞遗传学及生化特点比较[J]. 现代肿瘤医学, 2022, 30(9): 1664-1667.
[20] 崔珺, 朱红青, 刘凌泉, 等. 不同剂量硼替佐米联合地塞米松对多发性骨髓瘤T细胞亚群及血清C反应蛋白、β2-微球蛋白的影响[J]. 现代生物医学进展, 2020, 20(9): 1720-1723.
[21] Liang, L., Li, J., Fu, H., et al. (2019) Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma. Journal of Cancer, 10, 4852-4859. [Google Scholar] [CrossRef] [PubMed]
[22] Zamanian-Daryoush, M., Lindner, D., Tallant, T.C., et al. (2013) The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-Tumorigenic Effects. The Journal of Biological Chemistry, 288, 21237-21252. [Google Scholar] [CrossRef
[23] Clark, D.M. and Lampert, I.A. (1990) Apoptosis Is a Common Histopathological Finding in Myelodysplasia: The Correlate of Ineffective Haematopoiesis. Leukemia & Lymphoma, 2, 415-418. [Google Scholar] [CrossRef] [PubMed]
[24] Raza, A., Alvi, S., Broady-Robinson, L., et al. (1997) Cell Cycle Kinetic Studies in 68 Patients with Myelodysplastic Syndromes Following Intravenous Iodo-and/or Bromodeoxyuridine. Experimental Hematology, 25, 530-535.
[25] Kesaniemi, Y.A., Witztum, J.L. and Steinbrecher, U.P. (1983) Receptor-Mediated Catabolism of Low Density Lipoprotein in Man. Quantitation Using Glucosylated Low Density Lipoprotein. The Journal of Clinical Investigation, 71, 950-959. [Google Scholar] [CrossRef
[26] Tirado-Vélez, J.M., Benítez-Rondán, A., Cózar-Castellano, I., et al. (2012) Low-Density Lipoprotein Cholesterol Suppresses Apoptosis in Human Multiple Myeloma Cells. Annals of Hematology, 91, 83-88. [Google Scholar] [CrossRef] [PubMed]
[27] Tosi, M.R. and Tugnoli, V. (2005) Cholesteryl Esters in Malignancy. Clinica Chimica Acta, International Journal of Clinical Chemistry, 359, 27-45. [Google Scholar] [CrossRef] [PubMed]
[28] Ganjali, S., Banach, M., Pirro, M., et al. (2021) HDL and Cancer—Causality Still Needs to Be Confirmed? Update 2020. Seminars in Cancer Biology, 73, 169-177. [Google Scholar] [CrossRef] [PubMed]
[29] Yvan-Charvet, L., Pagler, T., Gautier, E.L., et al. (2010) ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation. Science, 328, 1689-1693. [Google Scholar] [CrossRef] [PubMed]